Member Publications

Cancer Related High Impact >10 Publications
(Jan 1, 2019- July 31, 2019)

*Cancer Center members in bold

  1. Achey R, Gittleman H, Schroer J, Khanna V, Kruchko C, Barnholtz-Sloan J. (2019) Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005-2015, using the Central Brain Tumor Registry of the United States. Neuro-oncology 3:380-391. PMC ID: PMC6380426
  2. Al-Mayhani T, Heywood R, Vemireddy V, Lathia J, Piccirillo S, Watts C. (2019) A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR. Neuro-oncology 6:719-729
  3. Arif A, Jia J, Willard B, Li X, Fox P. (2019) Multisite Phosphorylation of S6K1 Directs a Kinase Phospho-code that Determines Substrate Selection. Mol. Cell 3:446-457.e6. PMC ID: PMC6415305
  4. Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A, Delfino K, Fan Y, Zhao Z, Koyama T, Hollenbeck B, Qin R, Zahnd W, Zabor E, Kattan M, Vickers A. (2019) Guidelines for Reporting of Statistics for Clinical Research in Urology. Eur. Urol. 3:358-367. PMC ID: PMC6391870
  5. Bartlett N, Wilson W, Jung S, Hsi E, Maurer M, Pederson L, Polley M, Pitcher B, Cheson B, Kahl B, Friedberg J, Staudt L, Wagner-Johnston N, Blum K, Abramson J, Reddy N, Winter J, Chang J, Gopal A, Chadburn A, Mathew S, Fisher R, Richards K, Schöder H, Zelenetz A, Leonard J. (2019) Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J. Clin. Oncol. 21:1790-1799
  6. Blum A, Venkitachalam S, Ravillah D, Chelluboyina A, Kieber-Emmons A, Ravi L, Kresak A, Chandar A, Markowitz S, Canto M, Wang J, Shaheen N, Guo Y, Shyr Y, Willis J, Chak A, Varadan V, Guda K. (2019) Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer. Gastroenterology 6:1761-1774.
  7. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi A, Antin J, Arai S, Bickett K, Chen Y, Damon L, Efebera Y, Geller N, Giralt S, Hari P, Holtan S, Horowitz M, Jacobsohn D, Jones R, Liesveld J, Logan B, MacMillan M, Mielcarek M, Noel P, Pidala J, Porter D, Pusic I, Sobecks R, Solomon S, Weisdorf D, Wu J, Pasquini M, Koreth J. (2019) Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 3:e132-e143. PMC ID: PMC6503965
  8. Castinetti F, Waguespack S, Machens A, Uchino S, Lazaar K, Sanso G, Else T, Dvorakova S, Qi X, Elisei R, Maia A, Glod J, Lourenço D, Valdes N, Mathiesen J, Wohllk N, Bandgar T, Drui D, Korbonits M, Druce M, Brain C, Kurzawinski T, Patocs A, Bugalho M, Lacroix A, Caron P, Fainstein-Day P, Borson Chazot F, Klein M, Links T, Letizia C, Fugazzola L, Chabre O, Canu L, Cohen R, Tabarin A, Spehar Uroic A, Maiter D, Laboureau S, Mian C. (2019) Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol 3:213-220.
  9. Cato L, de Tribolet-Hardy J, Lee I, Rottenberg J, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik N, Göppert B, Ozgun F, van Royen M, Houtsmuller A, Vadhi R, Rao P, Li L, Balk S, Den R, Trock B, Karnes R, Jenkins R, Klein E, Davicioni E, Gruhl F, Long H, Liu X, Cato A, Lack N, Nelson P, Plymate S, Groner A, Brown M. (2019) ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell 3:401-413.e6.
  10. Cella D, Grünwald V, Escudier B, Hammers H, George S, Nathan P, Grimm M, Rini B, Doan J, Ivanescu C, Paty J, Mekan S, Motzer R. (2019) Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2:297-310.
  11. Chen X, Cai G, Liu C, Zhao J, Gu C, Wu L, Hamilton T, Zhang C, Ko J, Zhu L, Qin J, Vidimos A, Koyfman S, Gastman B, Jensen K, Li X. (2019) IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells. J. Exp. Med. 1:195-214. PMC ID: PMC6314525
  12. de Haas V, Ismaila N, Advani A, Arber D, Dabney R, Patel-Donelly D, Kitlas E, Pieters R, Pui C, Sweet K, Zhang L. (2019) Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. J. Clin. Oncol. 3:239-253. PMC ID: PMC6338392
  13. Di Luccia B, Gilfillan S, Cella M, Colonna M, Huang S. (2019) ILC3s integrate glycolysis and mitochondrial production of reactive oxygen species to fulfill activation demands. J. Exp. Med. :.
  14. Du Y, Duc N, Rasmussen S, Hilger D, Kubiak X, Wang L, Bohon J, Kim H, Wegrecki M, Asuru A, Jeong K, Lee J, Chance M, Lodowski D, Kobilka B, Chung K. (2019) Assembly of a GPCR-G Protein Complex. Cell 5:1232-1242.e11.
  15. Ferrer-Torres D, Nancarrow D, Steinberg H, Wang Z, Kuick R, Weh K, Mills R, Ray D, Ray P, Lin J, Chang A, Reddy R, Orringer M, Canto M, Shaheen N, Kresty L, Chak A, Wang T, Rubenstein J, Beer D. (2019) Constitutively Higher Level of GSTT2 in Esophageal Tissues From African Americans Protects Cells Against DNA Damage. Gastroenterology 5:1404-1415. PMC ID: PMC6441633
  16. Forero-Torres A, Ramchandren R, Yacoub A, Wertheim M, Edenfield W, Caimi P, Gutierrez M, Akard L, Escobar C, Call J, Persky D, Iyer S, DeMarini D, Zhou L, Chen X, Dawkins F, Phillips T. (2019) Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood 16:1742-1752. PMC ID: PMC6543513
  17. Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Calzada O, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Narayana Rao Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Karmali R, Kaplan J, Caimi P. (2019) Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J. Clin. Oncol. 6:471-480.
  18. Gillison M, Trotti A, Harris J, Eisbruch A, Harari P, Adelstein D, Sturgis E, Burtness B, Ridge J, Ringash J, Galvin J, Yao M, Koyfman S, Blakaj D, Razaq M, Colevas A, Beitler J, Jones C, Dunlap N, Seaward S, Spencer S, Galloway T, Phan J, Dignam J, Le Q. (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 10166:40-50. PMC ID: PMC6541928
  19. Gimple R, Kidwell R, Kim L, Sun T, Gromovsky A, Wu Q, Wolf M, Lv D, Bhargava S, Jiang L, Prager B, Wang X, Ye Q, Zhu, Z, Zhang G, Dong Z, Zhao L, Lee D, Bi J, Sloan A, Mischel P, Brown J, Cang H, Huan T, Mack S, Xie Q, Rich J. (2019) Glioma Stem Cell Specific Super Enhancer Promotes Polyunsaturated Fatty Acid Synthesis to Support EGFR Signaling. Cancer Discov :.
  20. Hassan R, Thomas A, Nemunaitis J, Patel M, Bennouna J, Chen F, Delord J, Dowlati A, Kochuparambil S, Taylor M, Powderly J, Vaishampayan U, Verschraegen C, Grote H, von Heydebreck A, Chin K, Gulley J. (2019) Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol :. PMC ID: PMC6439847
  21. Heianza Y, Sun D, Li X, DiDonato J, Bray G, Sacks F, Qi L. (2019) Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS Lost trial. Gut 2:263-270. PMC ID: PMC6275143
  22. Horwitz M, Wease S, Blackwell B, Valcarcel D, Frassoni F, Boelens J, Nierkens S, Jagasia M, Wagner J, Kuball J, Koh L, Majhail N, Stiff P, Hanna R, Hwang W, Kurtzberg J, Cilloni D, Freedman L, Montesinos P, Sanz G. (2019) Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. J. Clin. Oncol. 5:367-374. PMC ID: PMC6368416
  23. Hsi E, Li H, Nixon A, Schöder H, Bartlett N, LeBlanc M, Smith S, Kahl B, Leonard J, Evens A, Scott D, Rimsza L, Friedberg J. (2019) Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood 16:1762-1765. PMC ID: PMC6473498
  24. Hsieh P, Fan L, Sweet D, Jain M. (2019) The Krüppel-Like Factors and Control of Energy Homeostasis. Endocr. Rev. 1:137-152. PMC ID: PMC6334632
  25. Huyghe J, Bien S, Harrison T, Kang H, Chen S, Schmit S, Conti D, Qu C, Jeon J, Edlund C, Greenside P, Wainberg M, Schumacher F, Smith J, Levine D, Nelson S, Sinnott-Armstrong N, Albanes D, Alonso M, Anderson K, Arnau-Collell C, Arndt V, Bamia C, Banbury B, Baron J, Berndt S, Bézieau S, Bishop D, Boehm J, Boeing H, Brenner H, Brezina S, Buch S, Buchanan D, Burnett-Hartman A, Butterbach K, Caan B, Campbell P, Carlson C, Castellví-Bel S. (2019) Discovery of common and rare genetic risk variants for colorectal cancer. Nat. Genet. 1:76-87. PMC ID: PMC6358437
  26. Jarjour N, Schwarzkopf E, Bradstreet T, Shchukina I, Lin C, Huang S, Lai C, Cook M, Taneja R, Stappenbeck T, Randolph G, Artyomov M, Urban J, Edelson B. (2019) Bhlhe40 mediates tissue-specific control of macrophage proliferation in homeostasis and type 2 immunity. Nat. Immunol. 6:687-700. PMC ID: PMC6531324
  27. Jeong J, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat T, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno A, Ji P, Levine R, Godley L, Steidl U, Bieker J, List A, Saunthararajah Y, He C, Verma A, Wickrema A. (2019) Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discov :.
  28. Jeong J, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat T, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno A, Ji P, Levine R, Godley L, Steidl U, Bieker J, List A, Saunthararajah Y, He C, Verma A, Wickrema A. (2019) Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discov 6:778-795.
  29. Jeun M, Lee H, Park S, Do E, Choi J, Sung Y, Hong S, Kim S, Kim D, Kang J, Son H, Joo J, Song E, Hwang S, Park S, Yang D, Ye B, Byeon J, Choe J, Yang S, Moinova H, Markowitz S, Lee K, Myung S. (2019) A Novel Blood-Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein-2. Adv Sci (Weinh) 11:1802115. PMC ID: PMC6548955
  30. Jiang X, Finucane H, Schumacher F, Schmit S, Tyrer J, Han Y, Michailidou K, Lesseur C, Kuchenbaecker K, Dennis J, Conti D, Casey G, Gaudet M, Huyghe J, Albanes D, Aldrich M, Andrew A, Andrulis I, Anton-Culver H, Antoniou A, Antonenkova N, Arnold S, Aronson K, Arun B, Bandera E, Barkardottir R, Barnes D, Batra J, Beckmann M, Benitez J, Benlloch S, Berchuck A, Berndt S, Bickeböller H, Bien S, Blomqvist C, Boccia S, Bogdanova N, Bojesen S, Bolla M. (2019) Shared heritability and functional enrichment across six solid cancers. Nat Commun 1:431. PMC ID: PMC6347624
  31. Jin R, Liu L, Zhu W, Li D, Yang L, Duan J, Cai Z, Nie Y, Zhang Y, Gong Q, Song B, Wen L, Anderson J, Ai H. (2019) Iron oxide nanoparticles promote macrophage autophagy and inflammatory response through activation of toll-like Receptor-4 signaling. Biomaterials :23-30.
  32. Khorana A, Soff G, Kakkar A, Vadhan-Raj S, Riess H, Wun T, Streiff M, Garcia D, Liebman H, Belani C, O'Reilly E, Patel J, Yimer H, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer K, Kuderer N, Lyman G. (2019) Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N. Engl. J. Med. 8:720-728.
  33. Kim J, Miller J, Kotecha R, Chao S, Ahluwalia M, Peereboom D, Mohammadi A, Barnett G, Murphy E, Vogelbaum M, Angelov L, Abraham J, Moore H, Budd G, Suh J. (2019) Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro-oncology 5:659-668. PMC ID: PMC6502492
  34. Koeth R, Lam-Galvez B, Kirsop J, Wang Z, Levison B, Gu X, Copeland M, Bartlett D, Cody D, Dai H, Culley M, Li X, Fu X, Wu Y, Li L, DiDonato J, Tang W, Garcia-Garcia J, Hazen S. (2019) l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J. Clin. Invest. 1:373-387. PMC ID: PMC6307959
  35. Konstantinopoulos P, Waggoner S, Vidal G, Mita M, Moroney J, Holloway R, Van Le L, Sachdev J, Chapman-Davis E, Colon-Otero G, Penson R, Matulonis U, Kim Y, Moore K, Swisher E, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham J, Bobilev D, Dezube B, Munster P. (2019) Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol :. PMC ID: PMC6567832
  36. Kotecha R, Kim J, Miller J, Juloori A, Chao S, Murphy E, Peereboom D, Mohammadi A, Barnett G, Vogelbaum M, Angelov L, Suh J, Ahluwalia M. (2019) The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis. Neuro-oncology :.
  37. Koyfman S, Ismaila N, Crook D, D'Cruz A, Rodriguez C, Sher D, Silbermins D, Sturgis E, Tsue T, Weiss J, Yom S, Holsinger F. (2019) Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline. J. Clin. Oncol. 20:1753-1774.
  38. Lee D, Liu Y, Liao L, Li W, Danielpour D, Xu J. (2019) Neuroendocrine prostate carcinoma cells originate from the p63-expressing basal cells but not the pre-existing adenocarcinoma cells in mice. Cell Res. 5:420-422.
  39. Li X, Zhong M, Wang J, Wang L, Lin Z, Cao Z, Huang Z, Zhang F, Li Y, Liu M, Ma X. (2019) miR-301a promotes lung tumorigenesis by suppressing Runx3. Mol. Cancer 1:99. PMC ID: PMC6532219
  40. Liu X, Taftaf R, Kawaguchi M, Chang Y, Chen W, Entenberg D, Zhang Y, Gerratana L, Huang S, Patel D, Tsui E, Adorno-Cruz V, Chirieleison S, Cao Y, Harney A, Patel S, Patsialou A, Shen Y, Avril S, Gilmore H, Lathia J, Abbott D, Cristofanilli M, Condeelis J, Liu H. (2019) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Discov 1:96-113. PMC ID: PMC6328322
  41. Liu Z, Wang C, Yang J, Zhou B, Yang R, Ramachandran R, Abbott D, Xiao T. (2019) Crystal Structures of the Full-Length Murine and Human Gasdermin D Reveal Mechanisms of Autoinhibition, Lipid Binding, and Oligomerization. Immunity 1:43-49.e4. PMC ID: PMC6640092
  42. Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O, Lin Y, Braunschweig I, Hill B, Timmerman J, Deol A, Reagan P, Stiff P, Flinn I, Farooq U, Goy A, McSweeney P, Munoz J, Siddiqi T, Chavez J, Herrera A, Bartlett N, Wiezorek J, Navale L, Xue A, Jiang Y, Bot A, Rossi J, Kim J, Go W, Neelapu S. (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 1:31-42.
  43. Lu Y, Kweon S, Tanikawa C, Jia W, Xiang Y, Cai Q, Zeng C, Schmit S, Shin A, Matsuo K, Jee S, Kim D, Kim J, Wen W, Shi J, Guo X, Li B, Wang N, Zhang B, Li X, Shin M, Li H, Ren Z, Oh J, Oze I, Ahn Y, Jung K, Conti D, Schumacher F, Rennert G, Jenkins M, Campbell P, Hoffmeister M, Casey G, Gruber S, Gao J, Gao Y, Pan Z, Kamatani Y, Zeng Y. (2019) Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer. Gastroenterology 5:1455-1466. PMC ID: PMC6441622
  44. Luo D, Wang X, Zeng S, Ramamurthy G, Burda C, Basilion J. (2019) Targeted Gold Nanocluster-Enhanced Radiotherapy of Prostate Cancer. Small :e1900968.
  45. Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, Wang Q, Yang M, Kalady M, Qian J, Zhang A, Gupte A, Hamilton D, Zheng C, Yi Q. (2019) Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. Cell Metab. 1:143-156.e5.
  46. Maccaferri N, Zhao Y, Isoniemi T, Iarossi M, Parracino A, Strangi G, De Angelis F. (2019) Hyperbolic Meta-Antennas Enable Full Control of Scattering and Absorption of Light. Nano Lett. 3:1851-1859.
  47. Mack S, Singh I, Wang X, Hirsch R, Wu Q, Villagomez R, Bernatchez J, Zhu Z, Gimple R, Kim L, Morton A, Lai S, Qiu Z, Prager B, Bertrand K, Mah C, Zhou W, Lee C, Barnett G, Vogelbaum M, Sloan A, Chavez L, Bao S, Scacheri P, Siqueira-Neto J, Lin C, Rich J. (2019) Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. J. Exp. Med. 5:1071-1090. PMC ID: PMC6504206
  48. Martín-Garcia D, Navarro A, Valdés-Mas R, Clot G, Gutiérrez-Abril J, Prieto M, Ribera-Cortada I, Woroniecka R, Rymkiewicz G, Bens S, de Leval L, Rosenwald A, Ferry J, Hsi E, Fu K, Delabie J, Weisenburger D, de Jong D, Climent F, O'Connor S, Swerdlow S, Torrents D, Beltran S, Espinet B, González-Farré B, Veloza L, Costa D, Matutes E, Siebert R, Ott G, Quintanilla-Martinez L, Jaffe E, López-Otín C, Salaverria I, Puente X, Campo E, Beà S. (2019) CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma. Blood 9:940-951. PMC ID: PMC6396173
  49. Motzer R, Penkov K, Haanen J, Rini B, Albiges L, Campbell M, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee J, Vasiliev A, Miller W, Gurney H, Schmidinger M, Larkin J, Atkins M, Bedke J, Alekseev B, Wang J, Mariani M, Robbins P, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri T. (2019) Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 12:1103-1115.
  50. Nandadasa S, Kraft C, Wang L, O'Donnell A, Patel R, Gee H, Grobe K, Cox T, Hildebrandt F, Apte S. (2019) Secreted metalloproteases ADAMTS9 and ADAMTS20 have a non-canonical role in ciliary vesicle growth during ciliogenesis. Nat Commun 1:953. PMC ID: PMC6393521
  51. O'Connor O, Özcan M, Jacobsen E, Roncero J, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz S, Lennard A, Turgut M, Hamerschlak N, d'Amore F, Foss F, Kim W, Leonard J, Zinzani P, Chiattone C, Hsi E, Trümper L, Liu H, Sheldon-Waniga E, Ullmann C, Venkatakrishnan K, Leonard E, Shustov A. (2019) Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. J. Clin. Oncol. 8:613-623. PMC ID: PMC6494247
  52. Ornstein M, Rini B. (2019) Radical shifts in the first-line management of metastatic renal cell carcinoma. Nat Rev Clin Oncol 2:71-72.
  53. Ostrom Q, Coleman W, Huang W, Rubin J, Lathia J, Berens M, Speyer G, Liao P, Wrensch M, Eckel-Passow J, Armstrong G, Rice T, Wiencke J, McCoy L, Hansen H, Amos C, Bernstein J, Claus E, Houlston R, Il'yasova D, Jenkins R, Johansen C, Lachance D, Lai R, Merrell R, Olson S, Sadetzki S, Schildkraut J, Shete S, Andersson U, Rajaraman P, Chanock S, Linet M, Wang Z, Yeager M, Melin B, Bondy M, Barnholtz-Sloan J. (2019) Sex-specific gene and pathway modeling of inherited glioma risk. Neuro-oncology 1:71-82. PMC ID: PMC6303471
  54. Parikh S, Satwani P, Ahn K, Sahr N, Fretham C, Abraham A, Agrawal V, Auletta J, Abdel-Azim H, Copelan E, Diaz M, Dvorak C, Frangoul H, Freytes C, Gadalla S, Gale R, George B, Gergis U, Hashmi S, Hematti P, Hildebrandt G, Keating A, Lazarus H, Myers K, Olsson R, Prestidge T, Rotz S, Savani B, Shereck E, Williams K, Wirk B, Pasquini M, Loren A. (2019) Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatr :e190081. PMC ID: PMC6503511
  55. Pennell N, Neal J, Chaft J, Azzoli C, Jänne P, Govindan R, Evans T, Costa D, Wakelee H, Heist R, Shapiro M, Muzikansky A, Murthy S, Lanuti M, Rusch V, Kris M, Sequist L. (2019) SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2:97-104. PMC ID: PMC6524649
  56. Peters Y, Al-Kaabi A, Shaheen N, Chak A, Blum A, Souza R, Di Pietro M, Iyer P, Pech O, Fitzgerald R, Siersema P. (2019) Barrett oesophagus. Nat Rev Dis Primers 1:35.
  57. Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht A, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres M, Steensma D, Gloaguen S. (2019) Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood 10:1020-1030.
  58. Qu X, Li H, Braziel R, Passerini V, Rimsza L, Hsi E, Leonard J, Smith S, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg J, Fang M. (2019) Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood 1:81-93. PMC ID: PMC6318431
  59. Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo S, Borchiellini D, Szczylik C, Markus M, McDermott R, Bedke J, Tartas S, Chang Y, Tamada S, Shou Q, Perini R, Chen M, Atkins M, Powles T. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 12:1116-1127.
  60. Rini B, Powles T, Atkins M, Escudier B, McDermott D, Suarez C, Bracarda S, Stadler W, Donskov F, Lee J, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri T, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green M, Motzer R. (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 10189:2404-2415.
  61. Saha B, Tornai D, Kodys K, Adejumo A, Lowe P, McClain C, Mitchell M, McCullough A, Dasarathy S, Kroll-Desrosiers A, Barton B, Radaeva S, Szabo G. (2019) Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis. Hepatology :.
  62. Sandler K, Cook R, Ciezki J, Ross A, Pomerantz M, Nguyen P, Shaikh T, Tran P, Stock R, Merrick G, Demanes D, Spratt D, Abu-Isa E, Wedde T, Lilleby W, Krauss D, Shaw G, Alam R, Reddy C, Song D, Klein E, Stephenson A, Tosoian J, Hegde J, Yoo S, Fiano R, D'Amico A, Nickols N, Aronson W, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese T, Reiter R, Said J, Steinberg M, Horwitz E, Kupelian P, King C. (2019) Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur. Urol. :.
  63. Sanz-Garcia C, Poulsen K, Bellos D, Wang H, McMullen M, Li X, Chattopadhyay S, Sen G, Nagy L. (2019) The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute-on-chronic ethanol administration in mice. J. Hepatol. 5:974-984. PMC ID: PMC6462245
  64. Schmit S, Edlund C, Schumacher F, Gong J, Harrison T, Huyghe J, Qu C, Melas M, Van Den Berg D, Wang H, Tring S, Plummer S, Albanes D, Alonso M, Amos C, Anton K, Aragaki A, Arndt V, Barry E, Berndt S, Bezieau S, Bien S, Bloomer A, Boehm J, Boutron-Ruault M, Brenner H, Brezina S, Buchanan D, Butterbach K, Caan B, Campbell P, Carlson C, Castelao J, Chan A, Chang-Claude J, Chanock S, Cheng I, Cheng Y, Chin L, Church J. (2019) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J. Natl. Cancer Inst. 2:146-157. PMC ID: PMC6555904
  65. Seth P, Hsieh P, Jamal S, Wang L, Gygi S, Jain M, Coller J, Stamler J. (2019) Regulation of MicroRNA Machinery and Development by Interspecies S-Nitrosylation. Cell 5:1014-1025.e12. PMC ID: PMC6559381
  66. Shin Y, Sa J, Lee Y, Kim D, Chang N, Cho H, Son M, Oh M, Shin K, Lee J, Park J, Jo Y, Kim M, Paddison P, Tergaonkar V, Lee J, Nam D. (2019) PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. J. Exp. Med. 5:1120-1134. PMC ID: PMC6504209
  67. Singh A, Manjunath L, Kundu P, Sahoo S, Das A, Suma H, Fox P, Eswarappa S. (2019) Let-7a-regulated translational readthrough of mammalian AGO1 generates a microRNA pathway inhibitor. EMBO J. :e100727.
  68. Skolarus T, Metreger T, Wittmann D, Hwang S, Kim H, Grubb R, Gingrich J, Zhu H, Piette J, Hawley S. (2019) Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial. J. Clin. Oncol. 15:1326-1335. PMC ID: PMC6524986
  69. Smith H, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour C, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack J, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher N, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper C, Vargas Calderon A, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris L, Varadan V, Andrechek E, O'Toole S, Topisirovic I, Muller W. (2019) An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nat Commun 1:2901. PMC ID: PMC6603039
  70. Stein E, DiNardo C, Fathi A, Pollyea D, Stone R, Altman J, Roboz G, Patel M, Collins R, Flinn I, Sekeres M, Stein A, Kantarjian H, Levine R, Vyas P, MacBeth K, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen K, Wu B, Attar E, Tallman M, de Botton S. (2019) Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 7:676-687. PMC ID: PMC6384189
  71. Stephens D, Li H, Schöder H, Straus D, Moskowitz C, Leblanc M, Rimsza L, Bartlett N, Evens A, LaCasce A, Barr P, Knopp M, Hsi E, Leonard J, Kahl B, Smith S, Friedberg J. (2019) Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. Blood :.
  72. Stock W, Luger S, Advani A, Yin J, Harvey R, Mullighan C, Willman C, Fulton N, Laumann K, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield C, Sanford B, Marcucci G, Liedtke M, Claxton D, Foster M, Bogart J, Grecula J, Appelbaum F, Erba H, Litzow M, Tallman M, Stone R, Larson R. (2019) A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood 14:1548-1559. PMC ID: PMC6450431
  73. Stoffel E, McKernin S, Brand R, Canto M, Goggins M, Moravek C, Nagarajan A, Petersen G, Simeone D, Yurgelun M, Khorana A. (2019) Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J. Clin. Oncol. 2:153-164.
  74. Sun Z, Chen L, Xin H, Jiang Y, Huang Q, Cillo A, Tabib T, Kolls J, Bruno T, Lafyatis R, Vignali D, Chen K, Ding Y, Hu M, Chen W. (2019) A Bayesian mixture model for clustering droplet-based single-cell transcriptomic data from population studies. Nat Commun 1:1649. PMC ID: PMC6456731
  75. Walker J, Brady M, Wenzel L, Fleming G, Huang H, DiSilvestro P, Fujiwara K, Alberts D, Zheng W, Tewari K, Cohn D, Powell M, Van Le L, Davidson S, Gray H, Rose P, Aghajanian C, Myers T, Alvarez Secord A, Rubin S, Mannel R. (2019) Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J. Clin. Oncol. 16:1380-1390. PMC ID: PMC6544459
  76. Yang W, Warrington N, Taylor S, Whitmire P, Carrasco E, Singleton K, Wu N, Lathia J, Berens M, Kim A, Barnholtz-Sloan J, Swanson K, Luo J, Rubin J. (2019) Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci Transl Med 473:. PMC ID: PMC6502224
  77. Zarb Y, Weber-Stadlbauer U, Kirschenbaum D, Kindler D, Richetto J, Keller D, Rademakers R, Dickson D, Pasch A, Byzova T, Nahar K, Voigt F, Helmchen F, Boss A, Aguzzi A, Klohs J, Keller A. (2019) Ossified blood vessels in primary familial brain calcification elicit a neurotoxic astrocyte response. Brain 4:885-902. PMC ID: PMC6439320
  78. Zhao S, Lehrer J, Chang S, Das R, Erho N, Liu Y, Sjöström M, Den R, Freedland S, Klein E, Karnes R, Schaeffer E, Xu M, Speers C, Nguyen P, Ross A, Chan J, Cooperberg M, Carroll P, Davicioni E, Fong L, Spratt D, Feng F. (2019) The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J. Natl. Cancer Inst. 3:301-310.
  79. Zhao Y, Sun X, Hu D, Prosdocimo D, Hoppel C, Jain M, Ramachandran R, Qi X. (2019) ATAD3A oligomerization causes neurodegeneration by coupling mitochondrial fragmentation and bioenergetics defects. Nat Commun 1:1371. PMC ID: PMC6435701
  80. Zheng Z, Nayak L, Wang W, Yurdagul A, Wang X, Cai B, Lapping S, Ozcan L, Ramakrishnan R, Pestell R, Jain M, Tabas I. (2019) An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1. Blood 7:743-753. PMC ID: PMC6376283